Wells Fargo
CLDX icon

Wells Fargo’s Celldex Therapeutics CLDX Stock Holding History

Wells Fargo’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-68,900
Closed -$1.74M – 7064
2024
Q4 		$1.74M Buy
+68,900
New +$1.87M ﹤0.01% 3298

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's CLDX Position: Q2 2026 in Review

Wells Fargo increased its Celldex Therapeutics (CLDX) stake by 122% in Q2 2026, buying an estimated $1.39M and bringing the position to 78,176 shares worth $2.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3304.

Wells Fargo first reported a position in CLDX in Q2 2013 and has held it in 53 quarters since. The position peaked at $11.5M in Q2 2015. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Wells Fargo held 78,176 shares of Celldex Therapeutics worth $2.91M as of Q2 2026.
  • Wells Fargo bought 43,018 Celldex Therapeutics shares in Q2 2026, an estimated $1.39M.
  • Celldex Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3304 holding.
  • Wells Fargo first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Wells Fargo's Celldex Therapeutics position peaked at $11.5M in Q2 2015.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.